SOPHiA GENETICS SA·4/A

Apr 8, 8:46 AM ET

Xu Zhenyu 4/A

4/A · SOPHiA GENETICS SA · Filed Apr 8, 2026

Research Summary

AI-generated summary of this filing

Updated

SOPHiA GENETICS (SOPH) CSO Zhenyu Xu Receives RSU Award

What Happened
Zhenyu Xu, Chief Scientific Officer of SOPHiA GENETICS (SOPH), was granted a total of 277,607 restricted stock units (RSUs) on April 2, 2026 — 112,936 RSUs reported as an award and 164,671 RSUs reported as a derivative award. Each unit was issued at $0.00 (typical for RSU compensation), so no cash was exchanged. The filing was amended to correct the number of ordinary shares beneficially owned following the transaction to 650,052.

Key Details

  • Transaction date: April 2, 2026; reported on an amended Form 4 dated April 8, 2026 (original Form 4 filed April 3, 2026).
  • Grants: 112,936 RSUs (award) + 164,671 RSUs (derivative) = 277,607 RSUs; price reported $0.00 per unit.
  • Shares owned following transaction: 650,052 ordinary shares (corrected from an earlier erroneous amount).
  • Vesting (per footnotes): RSU grant under the 2021 Equity Incentive Plan — 25% vests on April 2, 2027, then remaining 75% vests in equal quarterly installments through April 2, 2030 (see footnote F1).
  • Amendment note (F2): This Form 4/A corrects the previously reported post-transaction beneficial ownership figure.
  • Additional footnote (F3) references a separate option vesting schedule (25% on April 2, 2027, then monthly through April 2, 2030).

Context
RSUs are compensation awards that convert to ordinary shares only upon vesting; they are not an out‑of‑pocket purchase by the insider and therefore do not necessarily indicate a personal market bet. Awards are standard executive compensation and align management with long‑term shareholder interests. The important practical takeaway for investors is the amended filing correcting ownership to 650,052 shares and the vesting schedule that will release shares over 2027–2030.

Insider Transaction Report

Form 4/AAmended
Period: 2026-04-02
Xu Zhenyu
Chief Scientific Officer
Transactions
  • Award

    Ordinary Shares

    [F1][F2]
    2026-04-02+112,936650,052 total
  • Award

    Share Option (Right to Buy)

    [F3]
    2026-04-02+164,671164,671 total
    Exercise: $5.04Exp: 2036-04-02Ordinary Shares (164,671 underlying)
Footnotes (3)
  • [F1]Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.
  • [F2]This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 112,936 ordinary shares due to an inadvertent error. The correct amount is 650,052 ordinary shares.
  • [F3]The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.
Signature
/s/ Elimara Brunetto as Attorney-in-fact for Zhenyu Xu|2026-04-08

Documents

1 file
  • 4
    wk-form4a_1775652404.xml

    FORM 4/A